National Pension Service Buys 82,853 Shares of Regeneron Pharmaceuticals, Inc. $REGN

National Pension Service grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 360,988 shares of the biopharmaceutical company’s stock after buying an additional 82,853 shares during the period. National Pension Service’s holdings in Regeneron Pharmaceuticals were worth $278,636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Basepoint Wealth LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $40,000. Rothschild Investment LLC boosted its holdings in Regeneron Pharmaceuticals by 60.1% during the fourth quarter. Rothschild Investment LLC now owns 975 shares of the biopharmaceutical company’s stock worth $753,000 after buying an additional 366 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $1,171,000. Moors & Cabot Inc. boosted its holdings in Regeneron Pharmaceuticals by 10.1% during the fourth quarter. Moors & Cabot Inc. now owns 785 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 72 shares during the last quarter. Finally, Huntington National Bank raised its position in shares of Regeneron Pharmaceuticals by 21.1% during the fourth quarter. Huntington National Bank now owns 642 shares of the biopharmaceutical company’s stock worth $496,000 after purchasing an additional 112 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on REGN shares. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Canaccord Genuity Group dropped their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Trading Down 1.0%

NASDAQ REGN opened at $621.52 on Friday. The stock’s 50-day moving average is $721.74 and its 200-day moving average is $745.26. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The firm has a market cap of $65.71 billion, a P/E ratio of 15.14, a P/E/G ratio of 1.39 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.